Amanta Healthcare IPO: Issue Booked Over 10 Times So Far, Check GMP And Other Key Details

Amanta Healthcare Ltd IPO (Amanta Healthcare IPO) opened for subscription on September 1. The pharmaceutical product maker’s public issue garnered strong investor interest on the first day of bidding. Here’s a look at some key things to know about Amanta Healthcare IPO as the issue continues to witness robust demand on the second day of bidding:

Amanta Healthcare IPO GMP

Amanta Healthcare’s unlisted shares are commanding a grey market premium (GMP) ranging between Rs 12 and Rs 29 per share according to multiple websites that monitor the movement of unlisted shares in the grey market. Given the GMP of Rs 29, the pharma company’s stock is expected to list at Rs 155 apiece, indicating a decent premium of over 23 per cent.

Amanta Healthcare IPO: Subscription On Day 2

On the second day of subscription, Amanta Healthcare IPO has been booked 10.79 times, cumulatively receiving applications for over 75.5 million shares compared to the 7 million shares on offer. So far, the Non-Institutional Investors are leading the demand for Amanta Healthcare’s shares, booking the issue 16.47 times on the second day of subscription. On the other hand, the retail individual investors and qualified institutional buyers booked the issue 14.48 times and 7 per cent respectively on September 2.

Amanta Healthcare IPO: Issue Size, Listing Date, Price Band

Amanta Healthcare IPO issue size aggregates to Rs 126 crore. The pharma company’s public issue consists of a totally fresh issue of 10 million shares.

Amanta Healthcare IPO price band has been fixed at Rs 120 to Rs 126 per share. Retail individual investors can bid for Amanta Healthcare IPO by applying for a minimum of 1 lot consisting of 119 shares totalling to a minimum investment of Rs 14,994.

Amanta Healthcare IPO share allotment status will be decided on September 4. Once the share allotment status of the Amanta Healthcare IPO is decided, successful bidders will receive shares of Amanta Healthcare in their demat accounts on September 8. Shares of Amanta Healthcare will tentatively list on the BSE and NSE. Amanta Healthcare IPO listing date is September 9.

Amanta Healthcare: Key Financials

In the fiscal year ending March 31, 2025, Amanta Healthcare’s total income stood at Rs 276.09 crore, falling by nearly 2 per cent compared to Rs 281.61 crore in the preceding fiscal. The profit-after-tax of the company for the fiscal year under review grew by over 189 per cent to Rs 10.5 crore compared to Rs 3.63 crore in the preceding fiscal. Amanta Healthcare's net worth also increased by more than 45 per cent to Rs 96.39 crore in the fiscal year ended March 31, 2025, compared to Rs 66.29 crore in the financial year ended March 31, 2024.

Amanta Healthcare: Business Model

Amanta Healthcare Ltd mentioned in its Red Herring Prospectus (RHP) it is engaged in developing, manufacturing and marketing a wide range of sterile liquid products. The company also makes medical devices. The company markets the products vis-à-vis national sales, international sales and product partnering with various foreign and Indian pharmaceutical companies. The company has a network of over 320 distributors and stockists in the domestic market. However, it also sells its products in geographies such as Africa, Latin America and the United Kingdom.

Amanta Healthcare Peers

Amanta Healthcare explained in its RHP that its listed peers include Denis Chem Lab Ltd. Some of the other competitors of the company include Aculife Healthcare Pvt Ltd, Axa Parenterals (India) Ltd, B. Braun Medical India Pvt Ltd, Fresenius Kabi India Pvt Ltd, Otsuka Pharmaceutical India Pvt Ltd and Shree Krishnakeshav Laboratories Ltd.

Amanta Healthcare IPO: Risks and Strengths

Here’s a look at some of the key risks related to Amanta Healthcare’s business according to the company’s RHP:

• Amanta Healthcare Ltd disclosed in its RHP that its manufacturing facility is located at a single location, thus any delay in production or shutdown of the facility can negatively affect the business and financial condition.

• The pharmaceutical company mentioned that its operations are labour intensive, thus events such as strikes, work stoppages and increased wage demands could adversely affect the company’s business.

• The medical devices manufacturer disclosed that its manufacturing license has been suspended in the past and any such suspensions in the future could adversely affect its business.

Here’s a look at some of the key strengths of Amanta Healthcare according to the company’s RHP:

• Amanta Healthcare claims that it is an established maker of pharmaceutical formulations and has a diverse product portfolio addressing a diverse market.

• The pharmaceutical company also claims to have large manufacturing capabilities and a wide domestic and international marketing network.

• Amanta Healthcare also claims to have an experienced management team supported by a large, diverse and skilled work force.

Amanta Healthcare IPO: Objective

Amanta Healthcare seeks to use the funds generated via the public issue for financing its capital expenditure requirements for setting up a new manufacturing line of ‘SteriPort’ the company’s large volume parenteral product. A portion of the proceeds will also be used for funding the establishment of a new manufacturing line for Small Volume Parenterals (SVPs) at Hariyala, Kheda, Gujarat. The funds will also be used for general corporate purposes.